High rate of complete remission and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant in patients with multiple myeloma. Results of a phase II prospective study

被引：0
|
作者：
Sahebi, F. [1 ]
Krishnan, A. [1 ]
Farol, L. [1 ]
Cai, J. -L. [1 ]
Somlo, G. [1 ]
Popplewell, L. [1 ]
Parker, P. [1 ]
Spielberger, R. [1 ]
Kogut, N. [1 ]
Karanes, C. [1 ]
Ruel, C. [1 ]
Frankel, P. [1 ]
Reburiano, E. [1 ]
Duarte, L. [1 ]
O'Donnell, L. [1 ]
Forman, S. [1 ]
机构：
[1] City Hope Med Ctr, Duarte, CA USA
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [31] BORTEZOMIB - MAINTENANCE POST AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IMPROVES REMISSION DURATION AND QUALITY OF RESPONSE IN ADULT (< 65 Y) MULTIPLE MYELOMA (MM) PATIENTS: AN UPDATE
    Bongarzoni, V.
    Greco, R.
    Anaclerico, B.
    Ronci, B.
    Fenu, S.
    Chierichini, A.
    Borza, P. Anticoli
    Angelini, S.
    Iacovino, P.
    Cedrone, M.
    Cortese, S.
    Bruno, R.
    Avvisati, G.
    Annino, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 581 - 581
  • [32] Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma
    Abidi, Muneer H.
    Gul, Zartash
    Abrams, Judith
    Ayash, Lois
    Deol, Abhinav
    Ventimiglia, Marie
    Lum, Lawrence
    Mellon-Reppen, Stephanie
    Al-Kadhimi, Zaid
    Ratanatharathorn, Voravit
    Zonder, Jeffrey
    Uberti, Joseph
    JOURNAL OF CHEMOTHERAPY, 2012, 24 (03) : 167 - 172
  • [33] Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
    Uy, G. L.
    Goyal, S. D.
    Fisher, N. M.
    Oza, A. Y.
    Tomasson, M. H.
    Stockerl-Goldstein, K.
    DiPersio, J. F.
    Vij, R.
    BONE MARROW TRANSPLANTATION, 2009, 43 (10) : 793 - 800
  • [34] Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
    G L Uy
    S D Goyal
    N M Fisher
    A Y Oza
    M H Tomasson
    K Stockerl-Goldstein
    J F DiPersio
    R Vij
    Bone Marrow Transplantation, 2009, 43 : 793 - 800
  • [35] Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
    Thomas, Sheeba K.
    Shah, Jatin J.
    Morin, Armando
    Morphey, Ashley N.
    Lee, Hans C.
    Manasanch, Elisabet E.
    Patel, Krina K.
    Kaufman, Gregory P.
    Iyer, Swami P.
    Feng, Lei
    Amini, Behrang
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Saini, Neeraj
    Srour, Samer A.
    Johnson, Ralph J.
    Crumpton, Brandon N.
    Stafford, Mildred D.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD, 2020, 136
  • [36] Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
    Stewart, AK
    Chen, CI
    Howson-Jan, K
    White, D
    Roy, J
    Kovacs, MJ
    Shustik, C
    Sadura, A
    Shepherd, L
    Ding, K
    Meyer, RM
    Belch, AR
    CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8170 - 8176
  • [37] Outcomes of Bortezomib Maintenance Compared with Lenalidomide Maintenance in Patients with High-Risk Multiple Myeloma and Chronic Kidney Disease Undergoing Autologous Stem Cell Transplant
    Nangia, Udit
    Chandramohan, Deepak
    Garapati, Hari Naga
    Simhadri, Prathap
    Mahajan, Neeraj
    BLOOD, 2024, 144 : 4754 - 4754
  • [38] Tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant
    Peles, Shachar
    Ruddell, Alisa
    Gao, Feng
    Abboud, Camille
    Cashen, Amanda
    Uy, Geoffrey
    Westervelt, Peter
    DiPersio, John F.
    Vij, Ravi
    BLOOD, 2007, 110 (11) : 358B - 359B
  • [39] Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.
    Ebraheem, Mohammad
    Cook, Joselle
    Kumar, Shaji
    Jevremovic, Dragan
    Dispenzieri, Angela
    Dingli, David
    Buadi, Francis
    Kapoor, Prashant
    Lacy, Martha
    Kourelis, Taxiarchis
    Warsame, Rahma M.
    Binder, Moritz
    Muchtar, Eli
    Hayman, Suzanne R.
    Go, Ronald S.
    Leung, Nelson
    Rajkumar, S. Vincent
    Kyle, Robert A.
    Gonsalves, Wilson I.
    Gertz, Morie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A Single-Arm, Phase II Study of Acalabrutinib As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Mantle Cell Lymphoma
    Tees, Michael T.
    Saba, Nakhle S.
    Kambhampati, Suman
    Flinn, Ian W.
    BLOOD, 2024, 144 : 6321 - 6322
12345